An Observational Study For Ambrisentan

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension, Pulmonary Cardiovascular Diseases Hypertension Lung Diseases Respiratory Tract Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site, Darlinghurst, New South Wales, Australia

About this study

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)

Treatment and study plan

Ambrisentan

Drug

ambrisentan

Primary outcomes

safety monitoring

Secondary outcomes

safety monitoring

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)

Acronym: VOLT

Important dates

Study start: 2008
Primary completion: 2013
Study completion: 2013
First posted: May 16, 2008
Registry last updated: Mar 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed